Compare stocks

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focused on the development and commercialization of antibody therapeutics for the treatment of cancer. The company is known for its proprietary antibody technologies, such as the DuoBody® and HexaBody® platforms, which enhance the efficacy and potency of treatments. Genmab's key products include DARZALEX® (daratumumab), a monoclonal antibody used in the treatment of multiple myeloma, which is marketed in collaboration with Janssen Biotech. Founded in 1999, Genmab operates a global network of offices and research facilities, including significant operations in the United States and the Netherlands. The company's strategic positioning is bolstered by its robust pipeline of investigational drugs and strategic partnerships with pharmaceutical leaders.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.